Orladeyo (Berotralstat)

Berotralstat, the active ingredient in Orladeyo, is a Kallikrein‑Kinin inhibitor presented as a tablet for oral use. It is indicated for the prophylactic treatment of hereditary angioedema attacks in adults. GNH USA supplies Orladeyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Orladeyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orladeyo is a targeted therapy that acts on the kallikrein‑kinin pathway to reduce the frequency of hereditary angioedema attacks.

- Hereditary angioedema (HAE): Decreases the number of swelling episodes in patients with type 1 or type 2 HAE. - Acquired angioedema: May reduce attack frequency in rare cases of acquired C1‑inhibitor deficiency. - Long‑term prophylaxis: Provides a convenient oral option for ongoing prevention of HAE attacks.

Adverse reactions reported with berotralstat are generally mild to moderate and reflect its systemic exposure.

Common Side Effects: - Dyspepsia: upset stomach or indigestion. - Diarrhea: loose, watery stools. - Abdominal pain: cramping or discomfort in the abdomen. - Nausea: feeling of queasiness. - Headache: mild to moderate head pain. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes indicating potential liver injury. - Angioedema: paradoxical swelling episodes. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thrombocytopenia: reduced platelet count. - Severe rash or skin reactions. - Acute pancreatitis: inflammation of the pancreas.

When prescribing beretralstat, clinicians should consider several safety aspects.

- Liver function monitoring: assess baseline enzymes and repeat periodically. - Pregnancy and lactation: avoid use unless the benefit outweighs potential risk. - Renal impairment: adjust use in patients with severe kidney disease. - Concomitant medications: review for drugs that affect liver metabolism. - Patient education: advise on recognizing signs of serious reactions. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Beretralstat may interact with other medicines that influence hepatic metabolism or affect the kallikrein‑kinin system.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase beretralstat exposure and risk of toxicity. - Hepatotoxic drugs: concurrent use can raise the risk of liver injury.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors: may modestly raise beretraltarget . - Medications that lower platelet . - Anticoagulants antico . - Herbal supplements . - Food . - Any .